The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC).
Shanthi Marur
Research Funding - Bristol-Myers Squibb
Shuli Li
No relevant relationships to disclose
Anthony Cmelak
No relevant relationships to disclose
Maura L. Gillison
No relevant relationships to disclose
Robert L. Ferris
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Julie E. Bauman
No relevant relationships to disclose
Weiqiang Zhao
No relevant relationships to disclose
William H. Westra
No relevant relationships to disclose
Christine H. Chung
Consultant or Advisory Role - Bristol-Myers Squibb
Lynne I. Wagner
No relevant relationships to disclose
David R. Trevarthen
No relevant relationships to disclose
Balkrishna N. Jahagirdar
No relevant relationships to disclose
A. Dimitrios Colevas
No relevant relationships to disclose
Barbara Burtness
Honoraria - Bristol-Myers Squibb